Peregrine Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Peregrine Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-125,653	Closed	-$5.99M	–	347
2021 Q4	$5.99M	Buy	125,653 +23,001	+22%	+$1.03M	0.12%	244
2021 Q3	$6.82M	Sell	102,652 -20,331	-17%	-$1.45M	0.14%	240
2021 Q2	$9.6M	Buy	122,983 +25,968	+27%	+$1.92M	0.17%	236
2021 Q1	$9.18M	Sell	97,015 -13,570	-12%	-$1.61M	0.17%	239
2020 Q4	$13.5M	Buy	110,585 +11,584	+12%	+$1.27M	0.26%	186
2020 Q3	$8.65M	Buy	+99,001	New	+$6.9M	0.23%	149

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Peregrine Capital Management's TPTX Position: Q1 2022 in Review

Peregrine Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022, closing a stake of 125,653 shares — an estimated $5.99M sold.

Peregrine Capital Management first reported a position in TPTX in Q3 2020 and held it in 6 quarters. The position peaked at $13.5M in Q4 2020. 155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

Peregrine Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Peregrine Capital Management sold 125,653 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $5.99M.
Peregrine Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
Peregrine Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $13.5M in Q4 2020.
155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Peregrine Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.